Chris Roberts jumps back in­to biotech with CSO gig at Black Di­a­mond; Trou­bled Five Prime ap­points in­ter­im CEO

Chris Roberts Black Di­a­mond

→ Af­ter spend­ing two years as en­tre­pre­neur-in-res­i­dence at SR One — the ven­ture arm of his for­mer em­ploy­er, Glax­o­SmithK­line Chris Roberts is back at the front­lines of biotech.

As CSO of Black Di­a­mond Ther­a­peu­tics, Roberts joins CEO David Ep­stein in dri­ving their tar­get­ed ki­nase in­hibitors to­ward the clin­ic. He will lead re­search and ear­ly de­vel­op­ment on the biotech’s MAP plat­form, which ze­roes in on al­losteric mu­ta­tions of onco­genes. Its lead can­di­date, BDTX-189, tar­gets EGFR and HER2 re­gard­less of tu­mor type.

Can­cer, and par­tic­u­lar­ly ge­net­ic dri­vers of the dis­ease, was some­thing Roberts had some ex­pe­ri­ence with as VP of chem­istry and ear­ly de­vel­op­ment at Sy­ros, where he fo­cused on drug­ging tran­scrip­tion and was cred­it­ed for guid­ing two as­sets in­to clin­i­cal de­vel­op­ment. Be­fore that, he had spear­head­ed in­fec­tious dis­ease projects at GSK and Genelabs

Cam­bridge, MA-based Black Di­a­mond has al­so re­cruit­ed Matt Lu­cas from Yu­man­i­ty Ther­a­peu­tics to lead chem­istry and Tai-An Lin from Mer­ck KGaA to lead bi­ol­o­gy. Its first Phase I/II tri­al is slat­ed for the first half of next year.

Things haven’t been the same for can­cer-fo­cused Five Prime Ther­a­peu­tics, ever since their part­nered drug cabi­ral­izum­ab in com­bi­na­tion with Op­di­vo showed signs of weak ef­fi­ca­cy and a trou­bling safe­ty pro­file in an ear­ly-stage pan­cre­at­ic can­cer study in late 2017. As a re­sult of that fail­ure, the com­pa­ny axed 41 jobs in Jan­u­ary — rough­ly 20% of the com­pa­ny’s work­force — to fo­cus on late-stage pipelines. The South San Fran­cis­co-based com­pa­ny has tapped William “Bill” Ringo as act­ing in­ter­im CEO, suc­ceed­ing Aron Knicker­bock­er “who has re­signed from the com­pa­ny to pur­sue new chal­lenges and op­por­tu­ni­ties.” Cur­rent­ly, Ringo is the chair­man of com­pa­ny’s board of di­rec­tors  — and de­spite his tem­po­rary new role, will re­main in that po­si­tion. Ringo’s past ex­pe­ri­ence in­cludes pres­i­dent and CEO of Ab­genix and gigs at Pfizer and Eli Lil­ly.

Nadir Mah­mood Nkar­ta

→ Af­ter NASH con­tender CymaBay Ther­a­peu­tics re­leased neg­a­tive da­ta back in June show­ing that its lead drug se­ladel­par per­formed worse than a place­bo at a three-month read­out from its on­go­ing 52-week mid-stage study, the com­pa­ny’s stock plum­met­ed about 44.5%. Now, its CMO Pol Boudes is hit­ting the ex­it “to ex­plore oth­er op­por­tu­ni­ties.” Be­fore join­ing CymaBay, Boudes served in the same po­si­tion at Am­i­cus Ther­a­peu­tics and held oth­er stints at Berlex Lab­o­ra­to­ries (lat­er merged with Bay­er Health­Care Phar­ma­ceu­ti­cals), Wyeth-Ay­erst Re­search, Hoff­mann-La Roche and Pas­teur-Merieux Serums & Vac­cines. The com­pa­ny has ini­ti­at­ed a search for a suc­ces­sor. 

→ Fol­low­ing plans to map out clin­i­cal man­u­fac­tur­ing of CAR-NK af­ter a $114 mil­lion Se­ries B round led by Sam­sara ear­li­er this month, Nkar­ta Ther­a­peu­tics has pro­mot­ed Nadir Mah­mood from SVP, cor­po­rate de­vel­op­ment to the new­ly-cre­at­ed po­si­tion of CBO. Mah­mood pre­vi­ous­ly head­ed cor­po­rate de­vel­op­ment at Sec­ond Genome and brings ex­pe­ri­ence from roles at Kythera Bio­phar­ma­ceu­ti­cals (ac­quired by Al­ler­gan) — where he over­saw the pre­clin­i­cal re­search for their lead mol­e­cule, Ky­bel­la — and Gold­man Sachs

An­drew Sto­ber En­cod­ed

→ Back in June, Or­chard Ther­a­peu­tics an­nounced the pric­ing of its IPO — 9 mil­lion Amer­i­can de­posi­tary shares (ADSs) for to­tal gross pro­ceeds of about $128 mil­lion. Now, the UK gene ther­a­py de­vel­op­er has an­nounced that its CCO, Ja­son Meyen­burg is leav­ing the com­pa­ny “to take on a chief ex­ec­u­tive role in the in­dus­try.” Un­til the com­pa­ny can find a per­ma­nent re­place­ment, Mark Rothera, the com­pa­ny’s pres­i­dent and CEO, will as­sume glob­al com­mer­cial lead­er­ship re­spon­si­bil­i­ties. 

→ Gene ther­a­py-fo­cused En­cod­ed Ther­a­peu­tics has ex­pand­ed its lead­er­ship team with the ap­point­ments of An­drew Sto­ber as chief man­u­fac­tur­ing of­fi­cer and David Mc­N­inch as CBO. Sto­ber joins the com­pa­ny af­ter lead­ing gene ther­a­py man­u­fac­tur­ing at No­var­tis and af­ter roles at AveX­is, Bio­gen, Mer­ck and Am­gen. Pre­vi­ous­ly, Mc­N­inch served as chief com­mer­cial of­fi­cer at Prothena and dur­ing his stint at In­ter­Mune he helped or­ga­nize the launch of the first treat­ment for IPF and the com­pa­ny’s lat­er ac­qui­si­tion by Roche. Mc­N­inch al­so spent time at Ipsen, Genen­tech, No­var­tis and As­traZeneca pri­or to his new gig.

David Mc­N­inch En­cod­ed

→ In April, Ever­est Med­i­cines inked a deal with Im­munomedics — mak­ing it one of the top 5 in-li­cens­ing com­pa­nies in Chi­na in the past 11 years. Ever­est is now bol­ster­ing its team with sev­er­al new ap­point­ments. Ja­son Brown, who has been serv­ing as the com­pa­ny’s SVP of busi­ness de­vel­op­ment, has been ap­point­ed to the po­si­tion of CBO. In ad­di­tion to his ap­point­ment, Ever­est has named pre­vi­ous Sanofi ex­ec, Frank Grams, as SVP of al­liance man­age­ment; for­mer Sanofi Chi­na head, Sophia Zhu, as SVP of port­fo­lio de­vel­op­ment and strate­gic plan­ning; Ex-Ab­bott gen­er­al man­ag­er, Alex Wang, as head of in­ter­na­tion­al busi­ness and for­mer head of fi­nance of Am­gen Chi­na, Daniel Weng, as vice pres­i­dent of fi­nance.

Flag­ship-backed Foghorn Ther­a­peu­tics has ex­pand­ed its lead­er­ship with the ap­point­ments of Samuel Agres­ta as CMO and Al­lan Reine as CFO. Agres­ta for­mer­ly served in the same po­si­tion at In­fin­i­ty Phar­ma­ceu­ti­cals — and has worked as vice pres­i­dent and head of clin­i­cal de­vel­op­ment at Agios Phar­ma­ceu­ti­cals, where he over­saw the de­vel­op­ment and reg­is­tra­tion of ivosi­denib (Tib­so­vo) and enasi­denib (Id­hi­fa). Reine hops on board af­ter serv­ing in the same po­si­tion at Pieris Phar­ma­ceu­ti­cals. Stints at Lom­bard Odi­er As­set Man­age­ment, SAC Cap­i­tal Ad­vi­sors and Alexan­dra In­vest­ment Man­age­ment dot Reine’s re­sume.

Salarius Phar­ma­ceu­ti­cals has ap­point­ed Scott Jor­dan on board as CBO and Mark Rosen­blum as ex­ec­u­tive vice pres­i­dent fi­nance and in­ter­im CFO. With these new ad­di­tions, the com­pa­ny can fur­ther op­er­a­tions in its lead clin­i­cal pro­grams in Ew­ing sar­co­ma and ad­vanced sol­id tu­mors to aim at pro­duc­ing po­ten­tial da­ta in 2020. Jor­dan tran­si­tioned to the role af­ter serv­ing as Salarius’ CFO. Pre­vi­ous­ly, he served as CFO at Be­ta Cat Phar­ma­ceu­ti­cals and chief in­vest­ment of­fi­cer at Stingray Ther­a­peu­tics. He’s al­so the co-founder and ad­vi­sor at Health­ios Xchange. Rosen­blum was pre­vi­ous­ly brought on to the com­pa­ny as a fi­nan­cial con­sul­tant to as­sist with the merge with Flex Phar­ma. Pri­or to that role, Rosen­blum served as chair­man and CEO at Ac­tive­Care.

→ Prince­ton, New Jer­sey-based Oys­ter Point Phar­ma has wel­comed Dan Lochn­er as CFO and John Snis­arenko as CCO. Lochn­er joins af­ter a gig as man­ag­ing di­rec­tor at Gold­man Sachs. Snis­arenko hops over to the com­pa­ny fol­low­ing time as group vice pres­i­dent and head of Shire’s (now Take­da) oph­thalmic busi­ness, lead­ing sales for Xi­idra, Lu­cen­tis, Rit­ux­an and Actem­ra.

in­sitro — led by AI star Daphne Koller — has added Matthew Ras­mussen as vice pres­i­dent of da­ta en­gi­neer­ing and Du­ane Valz as gen­er­al coun­sel. Ras­mussen joins the com­pa­ny from Myr­i­ad Ge­net­ics as vice pres­i­dent of soft­ware en­gi­neer­ing and a pre­vi­ous stint at Coun­syl. Valz joins from Zymer­gen — where he served as the com­pa­ny’s first in-house lawyer and gen­er­al coun­sel, help­ing to struc­ture their Se­ries B and C fi­nanc­ings. Valz held pre­vi­ous po­si­tions at Google, Ya­hoo! and Howard Rice Ne­merovs­ki Canady Falk & Rabkin (now com­bined with Arnold & Porter). 

→ Back in Ju­ly, Cel­gene col­lab­o­rat­ed with Nim­bus Ther­a­peu­tics to bag an op­tion for their ‘high­ly prized’ I/O tar­get, an HPK1 in­hibitor pro­gram. Now, Chris­tine Loh has joined Nim­bus as their SVP, head of bi­ol­o­gy af­ter spend­ing time as the vice pres­i­dent of trans­la­tion­al med­i­cine at Kymera Ther­a­peu­tics. Pre­vi­ous­ly, she served as the ex­ec­u­tive di­rec­tor of re­search — fo­cus­ing on he­mo­phil­ia and sick­le cell dis­ease — at Bio­gen spin­out Biover­a­tiv. She has held po­si­tions at Sir­tris, Pfiz­er and ICOS Cor­po­ra­tion

X4 Phar­ma­ceu­ti­cals — which col­lab­o­rat­ed with the Leukemia & Lym­phoma So­ci­ety in May to ac­cel­er­ate the de­vel­op­ment of their lead prod­uct can­di­date ma­vorix­afor for the treat­ment of Walden­ström’s macroglob­u­line­mia — has named one of its orig­i­nal founders, Re­na­to Skerlj, as SVP, re­search and de­vel­op­ment. He draws from his ex­pe­ri­ence as the in­ven­tor of both pler­ix­afor, a stem cell mo­bi­liz­er ap­proved by the FDA in 2008, and er­tapen­em, an an­ti-bac­te­r­i­al ap­proved by the FDA in 2001. Skerlj’s re­sume in­cludes gigs at Lyso­so­mal Ther­a­peu­tics, Gen­zyme and AnorMED

Vi­nee­ta Be­langer Busi­ness Wire

→ Two years af­ter Zosano Phar­ma re­port­ed pos­i­tive Phase III da­ta for its mi­cronee­dle patch sys­tem for de­liv­er­ing an old mi­graine drug — set­ting up a cam­paign to file an NDA — the com­pa­ny has brought on Dushyant Pathak as SVP of busi­ness de­vel­op­ment. Most re­cent­ly, Pathak served as the as­so­ciate vice chan­cel­lor of re­search, in­no­va­tion and tech­nol­o­gy com­mer­cial­iza­tion, as well as the ex­ec­u­tive di­rec­tor of Ven­ture Cat­a­lyst  at Uni­ver­si­ty of Cal­i­for­nia Davis. Pathak brings ex­pe­ri­ence from his times at iP­ier­ian, as CEO and pres­i­dent of Cellex­i­con, founder of Ven­tureEdge and roles at Axys Phar­ma­ceu­ti­cals and Ch­i­ron

→ While their lead drug can­di­date LYR-210 is in Phase II for the treat­ment of chron­ic rhi­nos­i­nusi­tis, ear, nose and throat dis­eases, Lyra Ther­a­peu­tics has added Vi­nee­ta Be­langer as the com­pa­ny’s SVP of clin­i­cal af­fairs. Be­langer most re­cent­ly served as vice pres­i­dent of clin­i­cal af­fairs at Ave­dro and has held po­si­tions at Iron­wood Phar­ma­ceu­ti­cals, Neu­ro­Vi­sion and Al­con.

Pe­ter Catal­i­no has as­sumed a new gig at Ver­tex as SVP, head glob­al mar­ket­ing. He tran­si­tions to the com­pa­ny af­ter time as glob­al busi­ness fran­chise head car­dio-meta­bol­ic med­i­cines at No­var­tis. While at No­var­tis he worked un­der Paul Hud­son — crank­ing out block­buster heart drug En­tresto  and con­tribut­ing to the Akcea-Io­n­is li­cense deal. Pre­vi­ous­ly, Catal­i­no was an as­so­ciate prin­ci­pal at McK­in­sey & Com­pa­ny

→ Last week, Soli­genix brought Jonathan Guar­i­no on board as their SVP and CFO, suc­ceed­ing Karen Krume­ich who hit the ex­it to pur­sue new op­por­tu­ni­ties. This week the com­pa­ny made the ad­di­tion of Mer­ck vet Daniel Ring as vice pres­i­dent of busi­ness de­vel­op­ment and strate­gic plan­ning. Ring brings ex­pe­ri­ence from his time as vice pres­i­dent of busi­ness de­vel­op­ment at Ex­ela Phar­ma Sci­ences and as ex­ec­u­tive di­rec­tor of cor­po­rate li­cens­ing at Mer­ck

Allen Poir­son has hopped to twoXAR as the com­pa­ny’s SVP of bio­phar­ma­ceu­ti­cal busi­ness de­vel­op­ment. Be­fore join­ing the AI-dri­ven com­pa­ny, Poir­son served as a part­ner at Sil­i­con Val­ley-based VC firm Mighty Cap­i­tal. He for­mer­ly served as the CEO of Sony sub­sidiary Sony Biotech­nol­o­gy and held po­si­tions at NASA and Howard Hugh­es Med­ical In­sti­tute

→ Med­ical de­vice com­pa­ny, BioVen­trix, has tapped Pe­dro Mar­ques as vice pres­i­dent of sales for the Eu­ro­pean mar­ket. Mar­ques pre­vi­ous stints in­clude roles as vice pres­i­dent of glob­al ac­cess and clin­i­cal de­vel­op­ment at Medtron­ic and as VP of in­ter­na­tion­al sales for Heart­Ware

Bio­Th­eryX — fo­cused on mul­ti-ki­nase in­hi­bi­tion and tar­get­ed pro­tein degra­da­tion — has wel­comed Al­ler­gan vet Jef­frey Ed­wards to its board of di­rec­tors. Ed­wards spent 22 years at Al­ler­gan — hold­ing sev­er­al roles in­clud­ing EVP, fi­nance and busi­ness de­vel­op­ment and CFO. 

Ted Love, cur­rent pres­i­dent and CEO of Glob­al Blood Ther­a­peu­tics — which re­cent­ly re­ceiv­ing pri­or­i­ty re­view from the FDA for its sick­le cell dis­ease drug — has joined the board of di­rec­tors at Por­to­la Phar­ma­ceu­ti­cals. Love pre­vi­ous­ly worked at Onyx Phar­ma­ceu­ti­cals, Nu­velo, Ther­a­vance and Genen­tech.

→ Cam­bridge-based Verve Ther­a­peu­tics — who is purs­ing a gene-edit­ing ap­proach to coro­nary artery dis­ease — can now count An­drew Geall, as a mem­ber of the com­pa­ny’s sci­en­tif­ic ad­vi­so­ry board. Geall is the vice pres­i­dent of for­mu­la­tions, an­a­lyt­ics and chem­istry at Avid­i­ty Bio­sciences

→  An­a­lysts hate to lose a biotech CFO they’ve come to trust and ad­mire — es­pe­cial­ly if they’re be­ing blind­sided by a sur­prise ex­it. And Alex­ion’s un­ex­pect­ed an­nounce­ment af­ter the mar­ket close on Tues­day that Paul Clan­cy is on his way out — to be re­placed by a strat­e­gy and busi­ness chief they know vir­tu­al­ly noth­ing about — qual­i­fied as a nasty shock for some high-pro­file com­pa­ny ob­servers. 

Arad­hana Sarin

The Q3 re­port will be a joint ef­fort of Clan­cy and his re­place­ment, Arad­hana Sarin, who will then pick up the CFO job as Clan­cy con­tin­ues to ad­vise the com­pa­ny in­to the mid­dle of next year. So what’s up with that? Clan­cy on­ly ar­rived 2 years ago, step­ping in from Bio­gen, where he al­so com­mand­ed lots of re­spect in a spot­light po­si­tion.

His hir­ing was seen as a coup for Alex­ion watch­ers, as CEO Lud­wig Hantson put to­geth­er his new team, re­or­ga­nized the com­pa­ny af­ter a bruis­ing in­ves­ti­ga­tion over ethics vi­o­la­tions, moved to Boston and laid out his ba­sic strat­e­gy on pro­tect­ing the big Soliris fran­chise. Sarin will take over with a lot to prove. And some an­a­lysts are set­ting the bar high. 

UP­DAT­ED: In a stun­ning turn­around, Bio­gen says that ad­u­canum­ab does work for Alzheimer's — but da­ta min­ing in­cites con­tro­ver­sy and ques­tions

Biogen has confounded the biotech world one more time.

In a stunning about-face, the company and its partners at Eisai say that a new analysis of a larger dataset on aducanumab has restored its faith in the drug as a game-changer for Alzheimer’s and, after talking it over with the FDA, they’ll now be filing for an approval of a drug that had been given up for dead.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,900+ biopharma pros reading Endpoints daily — and it's free.

Vas Narasimhan. Getty Images

UP­DAT­ED: Failed PhI­II fe­vip­iprant tri­als pour more cold wa­ter on No­var­tis' block­buster R&D en­gine — and briefly spread the chill to a high-pro­file biotech

Back in July, during an investor call where Novartis execs ran through an upbeat assessment of their Q2 performance, CEO Vas Narasimhan and development chief John Tsai were pressed to predict which of the two looming Phase III readouts — involving cardio drug Entresto and asthma therapy fevipiprant, respectively — had a higher likelihood of success. Tsai gave the PARAGON-HF study with Entresto minimally better odds, but Narasimhan emphasized that their strategy of giving fevipiprant to more severe patients gave them confidence.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,900+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: The FDA sets a reg­u­la­to­ry speed record, pro­vid­ing a snap OK for Ver­tex's break­through triplet for cys­tic fi­bro­sis

The FDA has approved Vertex’s new triplet for cystic fibrosis at a record-setting speed.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,900+ biopharma pros reading Endpoints daily — and it's free.

IM­brave150: Roche’s reg­u­la­to­ry crew plans a glob­al roll­out of Tecen­triq com­bo for liv­er can­cer as PhI­II scores a hit

Just weeks after Bristol-Myers Squibb defended its failed pivotal study pitting Opdivo against Nexavar in liver cancer, Roche says it’s beat the frontline challenge with a combination of their PD-L1 Tecentriq with Avastin. And now they’re rolling their regulatory teams in the US, Europe and China in search of a new approval — badly needed to boost a trailing franchise effort.
Given their breakthrough and Big Pharma status as well as the use of two approved drugs, FDA approval may well prove to be something of a formality. And the Chinese have been clear that they want new drugs for liver cancer, where lethal disease rates are particularly high.
Researchers at their big biotech sub, Genentech, say that the combo beat Bayer’s Nexavar on both progression-free survival as well as overall survival — the first advance in this field in more than a decade. We won’t get the breakdown in months of life gained, but it’s a big win for Roche, which has lagged far, far behind Keytruda and Opdivo, the dominant PD-1s that have captured the bulk of the checkpoint market so far.
Researchers recruited hepatocellular carcinoma — the most common form of liver cancer — patients for the IMbrave150 study who weren’t eligible for surgery ahead of any systemic treatment of the disease.
Roche has a fairly low bar to beat, with modest survival benefit for Nexavar, approved for this indication 12 years ago. But they also plan to offer a combo therapy that could have significantly less toxicity, offering patients a much easier treatment regimen.
Cowen’s Steven Scala recently sized up the importance of IMbrave150, noting:

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,900+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Clay Sie­gall’s $614M wa­ger on tu­ca­tinib pays off with solid­ly pos­i­tive piv­otal da­ta and a date with the FDA

Back at the beginning of 2018, Clay Siegall snagged a cancer drug called tucatinib with a $614 million cash deal to buy Cascadian. It paid off today with a solid set of mid-stage data for HER2 positive breast cancer that will in turn serve as the pivotal win Siegall needs to seek an accelerated approval in the push for a new triplet therapy.

And if all the cards keep falling in its favor, they’ll move from 1 drug on the market to 3 in 2020, which is shaping up as a landmark year as Seattle Genetics prepares for its 23rd anniversary on July 15.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,900+ biopharma pros reading Endpoints daily — and it's free.

David Liu, Liu Group

David Liu un­veils newest ad­vance­ment in CRISPR tech: Prime edit­ing

The researcher behind base-editing is out with what some scientists are hailing as the biggest advancement in CRISPR technology since that 2016 breakthrough: “prime editing.” The new molecular gadget is capable of erasing any base pair and stenciling in another and cutting or adding long segments of DNA without breaking both strands of the helix.

David Liu, base editing pioneer and founder of Beam Therapeutics, published the findings in Nature alongside Andrew Anzalone. They estimated that the breakthrough “in principle” puts 89% of human diseases in purview — although experts cautioned that human therapies were a long way off.

Bhaskar Chaudhuri. Frazier Healthcare Partners

Fra­zier Health­care Part­ner­s' der­ma­tol­ogy up­start at­tracts a mar­quee syn­di­cate, $94M+ for 'in-be­tween' top­i­cal drug

For the past three years Frazier Healthcare Partners’ Bhaskar Chaudhuri has been carefully and quietly grooming Arcutis Therapeutics, a new dermatology play he co-founded to deliver topical formulations of well-known drugs. Now that the biotech is poised to enter Phase III, he’s being joined by a marquee syndicate for its $94.5 million Series C.

HBM Healthcare Investments, Vivo Capital, BlackRock, Omega Funds, Pivotal BioVentures, and Goldman Sachs jumped on board, joining Bain Capital Life Sciences, OrbiMed and RA Capital Management in backing Arcutis’ lead topical cream for plaque psoriasis.

A new com­pa­ny en­ters the Tec­fidera fight, of­fer­ing to kill two birds

The remedy for the most common side effect for one of the most common multiple sclerosis drugs is simple: aspirin.

Taking aspirin with Biogen’s Tecfidera will reduce the flush, a sometimes painful form of red skin irritation, many patients experiences. The problem is that the aspirin has to be taken at least 30 minutes before Tecfidera, turning a simple twice-a-day, one-dose oral drug into a staggered two-drug regimen.

UP­DAT­ED: Bris­tol-My­ers makes Op­di­vo pitch for front­line lung can­cer with open la­bel PhI­II study

Despite a head start, when Bristol-Myers Squibb and its pioneering checkpoint inhibitor Opdivo suffered a key lung cancer setback in 2016, they found themselves relegated to the backseat as Merck’s Keytruda seized the wheel on the road to immunotherapy stardom. Bristol-Myers has since suffered blow after blow in its quest to take a big slice of the lucrative market, peppered with some small successes. On Tuesday, the New Jersey drugmaker touted positive data from a Phase III open-label study in a bid to carve itself a piece of the frontline lung cancer market.